Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Athira Pharma, Inc. stock logo
ATHA
Athira Pharma
$0.28
-3.4%
$0.27
$0.22
$3.67
$10.85M3.041.48 million shs55,547 shs
GRI Bio, Inc. stock logo
GRI
GRI Bio
$1.33
-1.4%
$2.04
$1.10
$81.77
$2.85M-1.67308,999 shs47,702 shs
PHAXIAM Therapeutics S.A. stock logo
PHXM
PHAXIAM Therapeutics
$3.10
$3.10
$2.50
$13.00
$10.58M2.352,472 shsN/A
Talphera, Inc. stock logo
TLPH
Talphera
$0.50
+1.1%
$0.52
$0.45
$1.19
$10.27M-0.1572,140 shs14,254 shs
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Athira Pharma, Inc. stock logo
ATHA
Athira Pharma
+0.31%+7.23%-2.07%-31.87%-88.75%
GRI Bio, Inc. stock logo
GRI
GRI Bio
+3.05%-2.17%-24.16%-83.10%-98.06%
PHAXIAM Therapeutics S.A. stock logo
PHXM
PHAXIAM Therapeutics
0.00%0.00%0.00%0.00%0.00%
Talphera, Inc. stock logo
TLPH
Talphera
-1.85%-2.76%+2.67%-14.79%-52.19%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Athira Pharma, Inc. stock logo
ATHA
Athira Pharma
3.1662 of 5 stars
3.05.00.00.02.22.51.3
GRI Bio, Inc. stock logo
GRI
GRI Bio
3.0242 of 5 stars
3.55.00.00.02.60.01.3
PHAXIAM Therapeutics S.A. stock logo
PHXM
PHAXIAM Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Talphera, Inc. stock logo
TLPH
Talphera
2.153 of 5 stars
3.82.00.00.02.90.00.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Athira Pharma, Inc. stock logo
ATHA
Athira Pharma
2.00
Hold$13.834,876.02% Upside
GRI Bio, Inc. stock logo
GRI
GRI Bio
3.00
Buy$22.001,552.64% Upside
PHAXIAM Therapeutics S.A. stock logo
PHXM
PHAXIAM Therapeutics
0.00
N/AN/AN/A
Talphera, Inc. stock logo
TLPH
Talphera
3.50
Strong Buy$5.00904.02% Upside

Current Analyst Ratings Breakdown

Latest GRI, ATHA, PHXM, and TLPH Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/27/2025
GRI Bio, Inc. stock logo
GRI
GRI Bio
Ascendiant Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$40.00 ➝ $34.00
4/14/2025
GRI Bio, Inc. stock logo
GRI
GRI Bio
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
4/1/2025
Talphera, Inc. stock logo
TLPH
Talphera
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$6.00 ➝ $6.00
(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Athira Pharma, Inc. stock logo
ATHA
Athira Pharma
N/AN/AN/AN/A$3.42 per shareN/A
GRI Bio, Inc. stock logo
GRI
GRI Bio
N/AN/AN/AN/A$5.22 per shareN/A
PHAXIAM Therapeutics S.A. stock logo
PHXM
PHAXIAM Therapeutics
$32.66M0.32N/AN/A$7.98 per share0.39
Talphera, Inc. stock logo
TLPH
Talphera
$27K378.17N/AN/A$0.83 per share0.60
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Athira Pharma, Inc. stock logo
ATHA
Athira Pharma
-$117.67M-$2.07N/AN/AN/AN/A-115.62%-88.94%7/30/2025 (Estimated)
GRI Bio, Inc. stock logo
GRI
GRI Bio
-$13.04M-$11.56N/AN/AN/AN/A-289.05%-165.01%8/12/2025 (Estimated)
PHAXIAM Therapeutics S.A. stock logo
PHXM
PHAXIAM Therapeutics
-$240KN/A0.00N/AN/AN/AN/AN/A
Talphera, Inc. stock logo
TLPH
Talphera
-$18.40M-$0.45N/AN/AN/AN/A-118.46%-65.82%8/12/2025 (Estimated)

Latest GRI, ATHA, PHXM, and TLPH Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2025Q1 2025
GRI Bio, Inc. stock logo
GRI
GRI Bio
-$4.08-$5.80-$1.72-$5.80N/AN/A
5/9/2025Q1 2025
Athira Pharma, Inc. stock logo
ATHA
Athira Pharma
-$0.20-$0.23-$0.03-$0.23N/AN/A
3/31/2025Q4 2024
Talphera, Inc. stock logo
TLPH
Talphera
-$0.21-$0.07+$0.14-$0.07N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Athira Pharma, Inc. stock logo
ATHA
Athira Pharma
N/AN/AN/AN/AN/A
GRI Bio, Inc. stock logo
GRI
GRI Bio
$1.91143.48%N/AN/A N/A
PHAXIAM Therapeutics S.A. stock logo
PHXM
PHAXIAM Therapeutics
N/AN/AN/AN/AN/A
Talphera, Inc. stock logo
TLPH
Talphera
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Athira Pharma, Inc. stock logo
ATHA
Athira Pharma
N/A
2.95
2.95
GRI Bio, Inc. stock logo
GRI
GRI Bio
N/A
3.10
3.10
PHAXIAM Therapeutics S.A. stock logo
PHXM
PHAXIAM Therapeutics
0.23
1.78
N/A
Talphera, Inc. stock logo
TLPH
Talphera
N/A
4.42
4.42

Institutional Ownership

CompanyInstitutional Ownership
Athira Pharma, Inc. stock logo
ATHA
Athira Pharma
57.12%
GRI Bio, Inc. stock logo
GRI
GRI Bio
33.95%
PHAXIAM Therapeutics S.A. stock logo
PHXM
PHAXIAM Therapeutics
0.40%
Talphera, Inc. stock logo
TLPH
Talphera
37.67%

Insider Ownership

CompanyInsider Ownership
Athira Pharma, Inc. stock logo
ATHA
Athira Pharma
22.10%
GRI Bio, Inc. stock logo
GRI
GRI Bio
0.13%
PHAXIAM Therapeutics S.A. stock logo
PHXM
PHAXIAM Therapeutics
1.94%
Talphera, Inc. stock logo
TLPH
Talphera
3.20%
CompanyEmployeesShares OutstandingFree FloatOptionable
Athira Pharma, Inc. stock logo
ATHA
Athira Pharma
4039.04 million31.01 millionOptionable
GRI Bio, Inc. stock logo
GRI
GRI Bio
12.14 million8.92 millionNot Optionable
PHAXIAM Therapeutics S.A. stock logo
PHXM
PHAXIAM Therapeutics
493.41 million3.35 millionNo Data
Talphera, Inc. stock logo
TLPH
Talphera
1920.50 million16.48 millionOptionable

Recent News About These Companies

Talphera (NASDAQ:TLPH) Stock Price Up 0.4% - Here's Why
Talphera reports Q4 EPS (7c) vs. (25c) last year
7TLPH : Earnings Outlook For Talphera

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Athira Pharma stock logo

Athira Pharma NASDAQ:ATHA

$0.28 -0.01 (-3.44%)
As of 11:30 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies. The company's product pipeline includes ATH-1020, an orally available brain-penetrant small molecule designed to enhance the HGF/MET system that is in Phase 1 clinical trials to treat neuropathic pain and neurodegenerative diseases; and ATH-1105, an oral small molecule drug candidate, which is a preclinical model for the treatment of Amyotrophic Lateral Sclerosis. In addition, it has a license agreement with Washington State University to offer for sale products covered by certain licensed patents, including dihexa, the chemical compound into which fosgonimeton metabolizes following administration; and collaboration and grant agreement with National Institutes of Health Grant to support ACT-AD Phase 2 clinical trial for fosgonimeton. The company was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. Athira Pharma, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.

GRI Bio stock logo

GRI Bio NASDAQ:GRI

$1.33 -0.02 (-1.39%)
As of 11:18 AM Eastern

GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development. The company also develops ADAIR and ADMIR for treatment of attention -deficit/hyperactivity disorder. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.

PHAXIAM Therapeutics stock logo

PHAXIAM Therapeutics NASDAQ:PHXM

$3.10 0.00 (0.00%)
As of 05/27/2025

PHAXIAM Therapeutics S.A., a biopharmaceutical company, focuses on developing treatments for resistant bacterial infections in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing a portfolio of phages targeting resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections, including staphylococcus aureus, escherichia coli, and pseudomonas aeruginosa. The company was formerly known as ERYTECH Pharma S.A. and changed its name to PHAXIAM Therapeutics S.A. in June 2023. PHAXIAM Therapeutics S.A. was incorporated in 2004 and is headquartered in Lyon, France.

Talphera stock logo

Talphera NASDAQ:TLPH

$0.50 +0.01 (+1.14%)
As of 11:39 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. The company was incorporated in 2005 and is headquartered in San Mateo, California.